Skip to main content

Table 2 Asexual and gametocyte prevalence during follow up

From: Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine

 AL onlyAL + primaquine day 1AL + primaquine day 3P-valueP-value
 % (n/N)% (n/N)% (n/N)(AL only vs AL + primaquine day 1)(AL only vs AL + primaquine day 3)
Asexual parasite prevalence by microscopy
 Day 215.1 (5/33)24.3 (9/37)13.5 (5/37)0.3380.845
 Day 3000
 AL onlyAL + primaquine day 1AL + primaquine day 3  
Gametocyte prevalence by QT-NASBA
 Day 190 (27/30)82.8 (29/35)96.8 (30/31)0.4740.437
 Day 426.7 (8/30)11.4 (4/35)25.8 (8/31)0.3640.382
 Day 813.3 (4/30)0.0 (0/35)6.4 (2/31)0.306
 Day 113.3 (1/30)0.0 (0/35)0.0 (0/31)
 Mean AUC (95% CI) of gametocyte density versus time*0.523 (0.467 – 0.579)0.530 (0.475 – 0.584)0.508 (0.450 – 0.563)0.5319
  1. AL artemether–lumefantrine, AUC area under the curve; CI confidence interval
  2. *P-value across the three treatment arms